Back to Search Start Over

Aβ 1-42 promotes microglial activation and apoptosis in the progression of AD by binding to TLR4.

Authors :
Dou RX
Zhang YM
Hu XJ
Gao FL
Zhang LL
Liang YH
Zhang YY
Yao YP
Yin L
Zhang Y
Gu C
Source :
Redox biology [Redox Biol] 2024 Dec; Vol. 78, pp. 103428. Date of Electronic Publication: 2024 Nov 14.
Publication Year :
2024

Abstract

Alzheimer's disease (AD) is one of the most common age-related neurodegenerative diseases and the most devastating form of senile dementia. It has a complex mechanism and no effective treatment. Exploring the pathogenesis of AD and providing ideas for treatment can effectively improve the prognosis of AD. Microglia were incubated with β-amyloid protein 1-42 (Aβ <subscript>1-42</subscript> ) to construct an AD cell model. After microglia were activated, cell morphology changed, the expression level of inflammatory factors increased, cell apoptosis was promoted, and the expression of microtubule-associated protein (Tau protein) and related proteins increased. By up-regulating and down-regulating Toll-like receptor 4 (TLR4), the cells were divided into TLR4 knockdown negative control group(Lv-NC group), TLR4 knockdown group(Lv-TLR4 group), TLR4 overexpression negative control group(Sh-NC group), and TLR4 overexpression group(Sh-TLR4 group). The expression of inflammatory factors was detected again. It was found that compared with the Lv-NC group, the expression of various inflammatory factors in the Lv-TLR4 group decreased, cell apoptosis was inhibited, and the expression of Tau protein and related proteins decreased. Compared with the Sh-NC group, the expression of inflammatory factors in the Sh-TLR4 group increased, cell apoptosis was promoted, and the expression of Tau protein and related proteins increased. These results indicate that Aβ <subscript>1-42</subscript> may promote microglial activation and apoptosis by binding to TLR4. Reducing the expression of TLR4 can reduce the occurrence of inflammatory response in AD cells and slow down cell apoptosis. Therefore, TLR4 is expected to become a new target for the prevention and treatment of AD.<br />Competing Interests: Declaration of competing interest The authors declare no competing interests.<br /> (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
2213-2317
Volume :
78
Database :
MEDLINE
Journal :
Redox biology
Publication Type :
Academic Journal
Accession number :
39550828
Full Text :
https://doi.org/10.1016/j.redox.2024.103428